Can creatine supplementation improve body composition and objective physical function in rheumatoid arthritis patients? A randomised controlled trial
Research output: Contribution to journal › Article › peer-review
Standard Standard
In: Arthritis Care and Research, Vol. 68, No. 6, 06.2016, p. 729-737.
Research output: Contribution to journal › Article › peer-review
HarvardHarvard
APA
CBE
MLA
VancouverVancouver
Author
RIS
TY - JOUR
T1 - Can creatine supplementation improve body composition and objective physical function in rheumatoid arthritis patients? A randomised controlled trial
AU - Wilkinson, T.J.
AU - Lemmey, A.B.
AU - Jones, J.
AU - Sheikh, F.
AU - Ahmad, Y.
AU - Chitale, S.
AU - Maddison, P.J.
AU - O'Brien, T.D.
N1 - This is the peer reviewed version of the following article: "Can creatine supplementation improve body composition and objective physical function in rheumatoid arthritis patients? A randomised controlled trial", which has been published in final form at http://dx.doi.org/10.1002/acr.22747. This article may be used for non-commercial purposes in accordance with Wiley Terms and Conditions for Self-Archiving. Betsi Cadwaladr University Health Board (BCUHB); Small Grants Committee (UK)
PY - 2016/6
Y1 - 2016/6
N2 - Rheumatoid cachexia (muscle wasting) in rheumatoid arthritis (RA) patients contributes to substantial reductions in strength and impaired physical function. The objective of this randomised control trial was to investigate the effectiveness of oral creatine (Cr) supplementation in increasing lean mass and improving strength and physical function in RA patients. Method. In a double-blind design, 40 RA patients, were randomised to either 12 weeks supplementation of Cr or placebo. Body composition (dual energy x-ray absorptiometry, DXA, and bioelectrical impedance spectroscopy, BIS), strength and objectively-assessed physical function were measured at: baseline, day 6, week 12 and week 24. Data analysis was performed by ANCOVA. Results. Creatine supplementation increased appendicular lean mass (ALM; a surrogate measure of muscle mass) by 0.52 (± 0.13) kg (P = 0.004 versus placebo), and total LM by 0.60 (± 0.37) kg (P = 0.158). The change in LM concurred with the gain in intracellular water (0.64 ± 0.22 L, P = 0.035) measured by BIS. Despite increasing ALM, Cr supplementation, relative to placebo, failed to improve isometric knee extensor (P = 0.408), handgrip strength (P = 0.833), or objectively-assessed physical function (P's = 0.335 – 0.764). Conclusion. In patients with RA, creatine supplementation increased muscle mass, but not strength or objective physical function. No treatment-related adverse effects were reported suggesting that Cr supplementation may offer a safe and acceptable adjunct treatment for attenuating muscle loss; this treatment may be beneficial for patients suffering from severe rheumatoid cachexia
AB - Rheumatoid cachexia (muscle wasting) in rheumatoid arthritis (RA) patients contributes to substantial reductions in strength and impaired physical function. The objective of this randomised control trial was to investigate the effectiveness of oral creatine (Cr) supplementation in increasing lean mass and improving strength and physical function in RA patients. Method. In a double-blind design, 40 RA patients, were randomised to either 12 weeks supplementation of Cr or placebo. Body composition (dual energy x-ray absorptiometry, DXA, and bioelectrical impedance spectroscopy, BIS), strength and objectively-assessed physical function were measured at: baseline, day 6, week 12 and week 24. Data analysis was performed by ANCOVA. Results. Creatine supplementation increased appendicular lean mass (ALM; a surrogate measure of muscle mass) by 0.52 (± 0.13) kg (P = 0.004 versus placebo), and total LM by 0.60 (± 0.37) kg (P = 0.158). The change in LM concurred with the gain in intracellular water (0.64 ± 0.22 L, P = 0.035) measured by BIS. Despite increasing ALM, Cr supplementation, relative to placebo, failed to improve isometric knee extensor (P = 0.408), handgrip strength (P = 0.833), or objectively-assessed physical function (P's = 0.335 – 0.764). Conclusion. In patients with RA, creatine supplementation increased muscle mass, but not strength or objective physical function. No treatment-related adverse effects were reported suggesting that Cr supplementation may offer a safe and acceptable adjunct treatment for attenuating muscle loss; this treatment may be beneficial for patients suffering from severe rheumatoid cachexia
U2 - 10.1002/acr.22747
DO - 10.1002/acr.22747
M3 - Article
VL - 68
SP - 729
EP - 737
JO - Arthritis Care and Research
JF - Arthritis Care and Research
SN - 2151-4658
IS - 6
ER -